Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of ...

AstraZeneca has acquired vaccine bioconjugation specialist Omn | AstraZeneca has acquired vaccine bioconjugation specialist ...

PepGen’s phase 2 myotonic dystrophy type 1 (DM1) data have met analysts’ best-case scenario, causing the biotech’s share ...

Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late ...

The U.S. Treasury's COINS Act proposal aims to shield U.S. biotech from Chinese competition, but insiders warn it will ...

Coherus Oncology is once again laying off 30% of its workforce as the biopharma narrows the focus of its investigational ...

AbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code. | AbCellera has become the ...

Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase ...

Boehringer Ingelheim is gearing up to take survodutide to regulators next year after the obesity drug proved its ...

Zura Bio’s tibulizumab has flunked a phase 2 hidradenitis suppurativa (HS) trial, prompting the biotech to end development in ...

Argenx has struck a deal to acquire Unnatural Products (UNP) for $550 million upfront, snapping up the Merck & Co.- and ...

Spruce Biosciences is spinning out a preclinical endocrinology program to be led by a newly formed subsidiary called Adrenyx ...